2024 Freshness Index... Who needs to freshen up [their pipeline]?
Of interest
1. Abbvie - almost 50% of their revenues coming from products >15 years of age, 60% > 10 years of age. If only there was a potential blockbuster AML treatment they could use to bolster their Venclexta program with, and to replace the revenue gaps created by Humira's loss of exclusivity?
2. Sanofi - 13 products in their clinical pipeline for haematology and oncology indications
3. Merck & Co (MSD) - 40% of revenues from products > 10 years old - bisantrene would pose a fantastic opportunity for the lifecycle management of Keyruda when patents expire in 2028.
4. Bristol Myers Squibb - with almost 70% of revenues coming from products > 10 years of age, and key patent expiries for Revlimid (2025/6), Eliquis (2027-29) and Opdivo (2028), BMS require additional M&A activity to bolster their pipeline.
https://www.evaluate.com/thought-leadership/the-2024-freshness-index-who-needs-to-freshen-up/#:~:text=Evaluate's%202024%20Freshness%20Index%20looks,over%2Dthe%2Dcounter%20drugs.
- Forums
- ASX - By Stock
- Industry news
2024 Freshness Index... Who needs to freshen up [their...
-
- There are more pages in this discussion • 674 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M |
Open | High | Low | Value | Volume |
$1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 807 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 2376 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 807 | 1.630 |
1 | 4000 | 1.600 |
2 | 2300 | 1.580 |
1 | 636 | 1.570 |
1 | 6000 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 2376 | 1 |
1.735 | 3313 | 1 |
1.750 | 2000 | 1 |
1.790 | 1000 | 1 |
1.800 | 2000 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |